Section 6 of 6
References
177 sources
- AAAAI Choosing Wisely list (opens in a new tab)
- AAAAI Urticaria Measures Set (2015) (opens in a new tab)
- AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026) (opens in a new tab)
- Abdalla et al. (2026) (opens in a new tab)
- ACAAI JTF chronic urticaria guideline announcement (2026) (opens in a new tab)
- Agache et al. (2021) (opens in a new tab)
- Altayf et al. (2026) (opens in a new tab)
- Alvarado et al. (2022) (opens in a new tab)
- Alvarado et al. (2026) (opens in a new tab)
- Balachandar et al. (2026) (opens in a new tab)
- Balp et al. (2018a) (opens in a new tab)
- Balp et al. (2018b) (opens in a new tab)
- Balp et al. (2022) (opens in a new tab)
- Balp et al. (2025) (opens in a new tab)
- Bernstein et al. (2014) (opens in a new tab)
- Bernstein et al. (2025) (opens in a new tab)
- Broder et al. (2015) (opens in a new tab)
- Celldex AAAAI 2026 data release (2026) (opens in a new tab)
- Celldex AAD 2026 quality of life release (2026) (opens in a new tab)
- Celldex EAACI 2023 urticaria release (2023) (opens in a new tab)
- Celldex EAACI 2026 angioedema release (2026) (opens in a new tab)
- Celldex EMBARQ-CSU enrollment release (2026) (opens in a new tab)
- Celldex EMBARQ-CSU initiation release (2024) (opens in a new tab)
- Celldex EMBARQ-CSU topline release (2026) (opens in a new tab)
- Celldex eosinophilic esophagitis phase 2 results release (2025) (opens in a new tab)
- Celldex first quarter results release (2026) (opens in a new tab)
- Celldex Form 10-K (2026) (opens in a new tab)
- Celldex Form 10-Q, third quarter (2026) (opens in a new tab)
- Celldex fourth quarter 2021 results release (2022) (opens in a new tab)
- Celldex fourth quarter 2025 results release (2026) (opens in a new tab)
- Celldex phase 1b CSU AAAAI release (2023) (opens in a new tab)
- Celldex phase 1b CSU EAACI release (2022) (opens in a new tab)
- Celldex phase 1b CSU initiation release (2020) (opens in a new tab)
- Celldex phase 2 CSU 52-week results release (2024) (opens in a new tab)
- Celldex phase 2 CSU angioedema release (2024) (opens in a new tab)
- Celldex phase 2 CSU first patient dosed release (2022) (opens in a new tab)
- Celldex presentation, EMBARQ-CSU topline results call (2026) (opens in a new tab)
- Celldex prurigo nodularis phase 2 results release (2026) (opens in a new tab)
- Celldex second quarter results release (2026) (opens in a new tab)
- Celldex subcutaneous formulation study release (2021) (opens in a new tab)
- Celldex third quarter results release (2026) (opens in a new tab)
- Chansakulporn et al. (2014) (opens in a new tab)
- Chu et al. (2025a) (opens in a new tab)
- Chu et al. (2025b) (opens in a new tab)
- Chu et al. (2026) (opens in a new tab)
- Chung et al. (2020) (opens in a new tab)
- Church et al. (2018) (opens in a new tab)
- ClinicalTrials.gov NCT04146129 (opens in a new tab)
- ClinicalTrials.gov NCT04538794 (opens in a new tab)
- ClinicalTrials.gov NCT05031624 (opens in a new tab)
- ClinicalTrials.gov NCT05368285 (opens in a new tab)
- ClinicalTrials.gov NCT06445023 (opens in a new tab)
- ClinicalTrials.gov NCT06445023 record history (opens in a new tab)
- ClinicalTrials.gov NCT06455202 (opens in a new tab)
- ClinicalTrials.gov NCT06455202 record history (opens in a new tab)
- ClinicalTrials.gov NCT07256392 (opens in a new tab)
- Confino-Cohen et al. (2012) (opens in a new tab)
- DeLong et al. (2008) (opens in a new tab)
- Doğan et al. (2026) (opens in a new tab)
- Dupixent prescribing information (2026) (opens in a new tab)
- Ertas et al. (2018) (opens in a new tab)
- Eun et al. (2019) (opens in a new tab)
- Fijen et al. (2023) (opens in a new tab)
- Fok et al. (2021) (opens in a new tab)
- Fricke et al. (2020) (opens in a new tab)
- Geissbühler et al. (2025) (opens in a new tab)
- Genentech Xolair cost page (2026) (opens in a new tab)
- Gericke et al. (2017) (opens in a new tab)
- Giménez-Arnau et al. (2025) (opens in a new tab)
- Giménez-Arnau et al. (2026a) (opens in a new tab)
- Giménez-Arnau et al. (2026b) (opens in a new tab)
- Gonçalo et al. (2021) (opens in a new tab)
- Graham et al. (2016) (opens in a new tab)
- Guillén-Aguinaga et al. (2016) (opens in a new tab)
- Hawro et al. (2018) (opens in a new tab)
- Healio (2026) (opens in a new tab)
- Hu et al. (2026) (opens in a new tab)
- Huang et al. (2025) (opens in a new tab)
- Jahn et al. (2026) (opens in a new tab)
- Jang and Lee (2026) (opens in a new tab)
- Jang et al. (2025) (opens in a new tab)
- Kanters et al. (2018) (opens in a new tab)
- Kaplan et al. (2013) (opens in a new tab)
- Kim et al. (2022) (opens in a new tab)
- Kocatürk et al. (2026a) (opens in a new tab)
- Kocatürk et al. (2026b) (opens in a new tab)
- Kolkhir et al. (2017a) (opens in a new tab)
- Kolkhir et al. (2017b) (opens in a new tab)
- Kolkhir et al. (2021) (opens in a new tab)
- Kolkhir et al. (2022a) (opens in a new tab)
- Kolkhir et al. (2022b) (opens in a new tab)
- Kolkhir et al. (2022c) (opens in a new tab)
- Kolkhir et al. (2023) (opens in a new tab)
- Kolkhir et al. (2025) (opens in a new tab)
- Kolkhir et al. (2026) (opens in a new tab)
- Konstantinou and Konstantinou (2019) (opens in a new tab)
- Kulthanan et al. (2018) (opens in a new tab)
- Kulthanan et al. (2019) (opens in a new tab)
- Lapi et al. (2016) (opens in a new tab)
- Lapi et al. (2026) (opens in a new tab)
- Mathias et al. (2012) (opens in a new tab)
- Maurer et al. (2013) (opens in a new tab)
- Maurer et al. (2017) (opens in a new tab)
- Maurer et al. (2020) (opens in a new tab)
- Maurer et al. (2023a) (opens in a new tab)
- Maurer et al. (2023b) (opens in a new tab)
- Maurer et al. (2023c) (opens in a new tab)
- Maurer et al. (2024a) (opens in a new tab)
- Maurer et al. (2024b) (opens in a new tab)
- Maurer et al. (2024c) (opens in a new tab)
- Maurer et al. (2024d) (opens in a new tab)
- Maurer et al. (2024e) (opens in a new tab)
- Maurer et al. (2025a) (opens in a new tab)
- Maurer et al. (2025b) (opens in a new tab)
- Metz et al. (2024) (opens in a new tab)
- Metz et al. (2025a) (opens in a new tab)
- Metz et al. (2025b) (opens in a new tab)
- Metz et al. (2025c) (opens in a new tab)
- Metz et al. (2025d) (opens in a new tab)
- Metz et al. (2025e) (opens in a new tab)
- Metz et al. (2025f) (opens in a new tab)
- Metz et al. (2026a) (opens in a new tab)
- Metz et al. (2026b) (opens in a new tab)
- Metz et al. (2026c) (opens in a new tab)
- Metz et al. (2026d) (opens in a new tab)
- Metz et al. (2026e) (opens in a new tab)
- Moñino-Romero et al. (2023) (opens in a new tab)
- Moñino-Romero et al. (2025) (opens in a new tab)
- Mosnaim et al. (2026a) (opens in a new tab)
- Mosnaim et al. (2026b) (opens in a new tab)
- Mosnaim et al. (2026c) (opens in a new tab)
- Mtibaa et al. (2026) (opens in a new tab)
- Muñoz et al. (2026a) (opens in a new tab)
- Muñoz et al. (2026b) (opens in a new tab)
- NICE remibrutinib draft guidance (2026) (opens in a new tab)
- NICE TA339 (2015) (opens in a new tab)
- Novartis Rhapsido savings and support page (2026) (opens in a new tab)
- O'Donnell et al. (1997) (opens in a new tab)
- Ocadiz-Ruiz et al. (2026) (opens in a new tab)
- Ohanyan et al. (2017) (opens in a new tab)
- Omlyclo prescribing information (2025) (opens in a new tab)
- Oregon PDAB Xolair affordability review (2026) (opens in a new tab)
- Regeneron Dupixent Colorado price disclosure (2026) (opens in a new tab)
- Rhapsido prescribing information (2026) (opens in a new tab)
- Riedl et al. (2025) (opens in a new tab)
- Riedl et al. (2026) (opens in a new tab)
- Ryan et al. (2022) (opens in a new tab)
- Saini et al. (2015) (opens in a new tab)
- Saini et al. (2025) (opens in a new tab)
- Schoepke et al. (2019) (opens in a new tab)
- Shaker et al. (2020) (opens in a new tab)
- Soong et al. (2025a) (opens in a new tab)
- Soong et al. (2025b) (opens in a new tab)
- Stull et al. (2017) (opens in a new tab)
- Sussman et al. (2018) (opens in a new tab)
- Tan et al. (2025) (opens in a new tab)
- Terhorst-Molawi et al. (2023) (opens in a new tab)
- Tharp et al. (2019) (opens in a new tab)
- Tsai et al. (2022) (opens in a new tab)
- Viegas et al. (2025) (opens in a new tab)
- Weller et al. (2013) (opens in a new tab)
- Weller et al. (2014) (opens in a new tab)
- Weller et al. (2020a) (opens in a new tab)
- Weller et al. (2020b) (opens in a new tab)
- Weller et al. (2025a) (opens in a new tab)
- Weller et al. (2025b) (opens in a new tab)
- Wertenteil et al. (2019) (opens in a new tab)
- WHO Proposed INN List 125 (2021) (opens in a new tab)
- Williams et al. (2018a) (opens in a new tab)
- Williams et al. (2018b) (opens in a new tab)
- Xiong et al. (2025) (opens in a new tab)
- Xolair prescribing information (2026) (opens in a new tab)
- Yosipovitch et al. (2026) (opens in a new tab)
- Yücel and Ünal (2026) (opens in a new tab)
- Zhao et al. (2025) (opens in a new tab)
- Zuberbier et al. (2010) (opens in a new tab)
- Zuberbier et al. (2026) (opens in a new tab)